Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 9/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102586 | 0.95 | PDK2 (0.38) | PDK2PIK3CDALOX5APFEN1DHODH | |
| SCHEMBL1102602 | 0.95 | PDK2 (0.38) | PDK2PIK3CDALOX5APFEN1DHODH | |
| SCHEMBL1102965 | 0.93 | TNF (0.39) | PDK2PIK3CDDHODHTNFBACE1 | |
| SCHEMBL1102682 | 0.92 | PDK2 (0.38) | PDK2PIK3CDDHODHTNF | |
| SCHEMBL1102563 | 0.92 | PDK2 (0.40) | PDK2PIK3CDDHODHTNF | |
| SCHEMBL1102745 | 0.91 | TDO2 (0.37) | PDK2PIK3CDTDO2 | |
| SCHEMBL1102894 | 0.91 | PDK2 (0.39) | PDK2PIK3CDDHODHTNF | |
| SCHEMBL1102578 | 0.91 | PDK2 (0.41) | PDK2PIK3CDTNF | |
| SCHEMBL1102813 | 0.91 | PDK2 (0.39) | PDK2PIK3CDDHODHTNF | |
| SCHEMBL1103695 | 0.91 | PDK2 (0.40) | PDK2PIK3CDTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | PDK2 1930/4885PIK3CD 1649/4885ALOX5AP 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.